Subsidiary of ApicHope Pharmaceutical Group (300723.SZ) has been approved to conduct clinical trials for the innovative drug APH03571 tablets.
Yi Pin Hong (300723.SZ) announced that recently, the company's wholly-owned subsidiary, Guangzhou Yi Pin Hong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of the innovative drug APH03571 developed independently by the company. The company has also received the "Drug Clinical Trial Approval Notice" and will soon commence clinical trials. APH03571 is a treatment drug developed by the company for adult patients with recurrent or refractory acute myeloid leukemia carrying the FLT3 (FMS-like tyrosine kinase 3) mutation.
ApicHope Pharmaceutical Group (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Group Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of the innovative drug APH03571 tablets developed independently by the company. The company has also received the "Drug Clinical Trial Approval Notice" and will soon commence clinical trials. APH03571 is a treatment drug developed by the company for adult patients with relapsed or refractory acute myeloid leukemia carrying FLT3 (FMS-like tyrosine kinase 3) mutations.
Related Articles
On June 10th, AAC TECH (02018) spent 13.1964 million Hong Kong dollars to repurchase 300,000 shares.
C&D INTL GROUP (01908) will distribute a final dividend of 0.9 Hong Kong dollars per share on July 16th.
ZHIHU-W (02390) spent 132,200 US dollars on repurchasing 125,600 shares on June 9th.
On June 10th, AAC TECH (02018) spent 13.1964 million Hong Kong dollars to repurchase 300,000 shares.
C&D INTL GROUP (01908) will distribute a final dividend of 0.9 Hong Kong dollars per share on July 16th.
ZHIHU-W (02390) spent 132,200 US dollars on repurchasing 125,600 shares on June 9th.
RECOMMEND
